Aurigene Discovery Technologies Limited

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
IRAK4Small molecule
Acute Myeloid LeukemiaNon-Hodgkin Lymphoma
Relapsed/Refractory Acute Myeloid Leukemia, Primary Central Nervous System Lymphoma
Phase 1
CBP/p300 (bromodomain)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
EmavusertibPhase 1/2Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma …
Est. primary completion 2027-07 · NCT03328078 · CT.gov ↗
What to watch
November 2027 (1)
EmavusertibPhase 2Chronic Lymphocytic Leukemia, B-cell Malignancies
Est. primary completion 2027-11 · NCT07271667 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.